. . . . . . . . . . . . . . . . . . . . "Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain. Gabapentin is well tolerated in most patients, has a relatively mild side-effect profile, and passes through the body unmetabolized."@en . . . . . "approved"@en . "Less than 3% of gabapentin circulates bound to plasma protein."@en . "60142-96-3"@en . . . "Take without regard to meals."@en . "investigational"@en . . . . . . . . . . . . . . . . . . . "Gabapentinum"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Gabapentin"@en . . . . "Humans and other mammals"@en . . " "@en . "Gabapentine"@en . "5-7 hours"@en . . . . . . . . . . "# Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S: Efficacy of gabapentin in migraine prophylaxis. Headache. 2001 Feb;41(2):119-28. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11251695 # Backonja MM, Serra J: Pharmacologic management part 1: better-studied neuropathic pain diseases. Pain Med. 2004 Mar;5 Suppl 1:S28-47. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14996228 # Choudhuri I, Sarvananthan N, Gottlob I: Survey of management of acquired nystagmus in the United Kingdom. Eye. 2007 Sep;21(9):1194-7. Epub 2006 May 26. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16732211 # Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G: Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2000 Sep;2(3 Pt 2):249-55. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11249802 # Su TZ, Feng MR, Weber ML: Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther. 2005 Jun;313(3):1406-15. Epub 2005 Mar 15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15769862"@en . . . . . . . . . . . . . . . . . . "* 58\u00B16 L"@en . . . . . . . "Gabapentin is eliminated from the systemic circulation by renal excretion as unchanged drug. Gabapentin is not appreciably metabolized in humans."@en . . . . . "For the management of postherpetic neuralgia in adults and as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy."@en . . . . . . . "Gabapentin interacts with cortical neurons at auxillary subunits of voltage-sensitive calcium channels. Gabapentin increases the synaptic concentration of GABA, enhances GABA responses at non-synaptic sites in neuronal tissues, and reduces the release of mono-amine neurotransmitters. One of the mechanisms implicated in this effect of gabapentin is the reduction of the axon excitability measured as an amplitude change of the presynaptic fibre volley (FV) in the CA1 area of the hippocampus. This is mediated through its binding to presynaptic NMDA receptors. Other studies have shown that the antihyperalgesic and antiallodynic effects of gabapentin are mediated by the descending noradrenergic system, resulting in the activation of spinal alpha2-adrenergic receptors. Gabapentin has also been shown to bind and activate the adenosine A1 receptor."@en . . . "* 190 mL/min"@en . . . . . "Symptoms of overdose include ataxia, labored breathing, ptosis, sedation, hypoactivity, and excitation."@en . . "Neurontin"@en . . . . . . . . . . . . . . . . "Avoid alcohol."@en . . "Gabapentino"@en . . . . . "Rapid. Absorbed in part by the L-amino acid transport system, which is a carrier-mediated, saturable transport system; as the dose increases, bioavailability decreases. Bioavailability ranges from approximately 60% for a 900 mg dose per day to approximately 27% for a 4800 milligram dose per day. Food has a slight effect on the rate and extent of absorption of gabapentin (14% increase in AUC)."@en . . . . . . . . . . . . . . . . . "Donald E. Butler, Barbara J. Greenman, \"Gabapentin mohohydrate and a process for producing the same.\" U.S. Patent US4960931, issued May, 1978."@en . "Gabapentina"@en . . . . . . . . . . . "Gabapetin"@en . . . . "Gabapentin GR"@en . . . . . . . . . . . . "1-(Aminomethyl)cyclohexaneacetic acid"@en .